歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Apoptosis > PI-103

瀏覽歷史

S81467

PI-103

源葉(MedMol) 98%
  • 英文名:
  • PI-103
  • 別名:
  • PI 103;3-[4-(4-嗎啉基吡啶并[3',2',4,5]呋喃并[3,2-d]嘧啶-2-基]苯酚
  • CAS號:
  • 371935-74-9
  • 分子式:
  • C19H16N4O3
  • 分子量:
  • 348.36
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購物車...
源葉(MedMol) S81467-1mg 98% ¥142.80元 8 - - - EA 加入購物車
源葉(MedMol) S81467-2mg 98% ¥238.00元 10 - - - EA 加入購物車
源葉(MedMol) S81467-5mg 98% ¥408.00元 10 - - - EA 加入購物車
源葉(MedMol) S81467-10mg 98% ¥544.00元 7 - - - EA 加入購物車
源葉(MedMol) S81467-25mg 98% ¥1088.00元 2 - - - EA 加入購物車
源葉(MedMol) S81467-50mg 98% ¥1496.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S81467-100mg 98% ¥2040.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy
  • 靶點(diǎn): p110α:8 nM (IC50);p110β:88 nM (IC50);p110δ:48 nM (IC50);p110γ:150 nM (IC50);mTORC1:20 nM (IC50);mTORC2:83 nM (IC50);PI3KC2β:26 nM (IC50);PI3KC2α:1 μM (IC50);hsVPS34:2.3 μM (IC50);DNA-PK:2 nM (IC50);ATR:850 nM (IC50);ATM:920 nM (IC50);PI4KIIIβ:50 μM (IC50);Apoptosis;?DNA-PK;?PI3K;?mTOR;?Autophagy
  • 體內(nèi)研究:
    PI-103 shows therapeutic activity against a range of human tumor xenografts, exhibiting inhibition of angiogenesis, invasion, and metastasis, as well as direct antiproliferative effects. PI-103 induces immunosuppression promoting in vivo tumor growth and inhibiting apoptosis. Tumors from PI-103-treated mice shows higher levels of cyclin D1 and more proliferating cells
  • 參考文獻(xiàn):
    1. Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-39. 2. Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110 alpha. Cell. 2006 May 19;125(4):733-47. 3. Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22(9):1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22(9):1698-706. 4. López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61.
  • 溶解性: DMSO  :  10  mg/mL  (28.71  mM;  Need  ultrasonic)
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.871 ml 14.353 ml 28.706 ml
    5 mM 0.574 ml 2.871 ml 5.741 ml
    10 mM 0.287 ml 1.435 ml 2.871 ml
    50 mM 0.057 ml 0.287 ml 0.574 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy
  • 靶點(diǎn): p110α:8 nM (IC50);p110β:88 nM (IC50);p110δ:48 nM (IC50);p110γ:150 nM (IC50);mTORC1:20 nM (IC50);mTORC2:83 nM (IC50);PI3KC2β:26 nM (IC50);PI3KC2α:1 μM (IC50);hsVPS34:2.3 μM (IC50);DNA-PK:2 nM (IC50);ATR:850 nM (IC50);ATM:920 nM (IC50);PI4KIIIβ:50 μM (IC50);Apoptosis;?DNA-PK;?PI3K;?mTOR;?Autophagy
  • 體內(nèi)研究:
    PI-103 shows therapeutic activity against a range of human tumor xenografts, exhibiting inhibition of angiogenesis, invasion, and metastasis, as well as direct antiproliferative effects. PI-103 induces immunosuppression promoting in vivo tumor growth and inhibiting apoptosis. Tumors from PI-103-treated mice shows higher levels of cyclin D1 and more proliferating cells
  • 參考文獻(xiàn):
    1. Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-39. 2. Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110 alpha. Cell. 2006 May 19;125(4):733-47. 3. Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22(9):1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22(9):1698-706. 4. López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61.
  • 溶解性: DMSO  :  10  mg/mL  (28.71  mM;  Need  ultrasonic)
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.871 ml 14.353 ml 28.706 ml
    5 mM 0.574 ml 2.871 ml 5.741 ml
    10 mM 0.287 ml 1.435 ml 2.871 ml
    50 mM 0.057 ml 0.287 ml 0.574 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。
点击收缩